Enteric-Coated Metformin for Localized Intestinal Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, obesity, and metabolic disorders, such as metformin, pose risks due to systemic bioavailability and side effects, particularly in patients with impaired renal function, and existing therapies have limitations in efficacy and safety, especially for patients with cardiovascular or liver issues.
Innovation Solution
Compositions of biguanide or related heterocyclic compounds, including metformin, are designed to minimize systemic bioavailability by targeted release in specific intestinal regions, using formulations like enteric coatings and modified release systems to reduce plasma concentrations and enhance localized action, thereby minimizing systemic exposure and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metformin is administered systemically to treat type II diabetes, then blood glucose levels are lowered and glucose tolerance is improved, but the risk of lactic acidosis increases in patients with impaired renal function
Solution Approach 1:
The patent applies local quality by targeting metformin delivery to specific intestinal regions (upper intestine, lower intestine, or both) rather than systemic distribution. The formulation is designed to release the biguanide compound locally in the intestine where it can modulate metabolic hormones and improve glucose tolerance, while avoiding systemic circulation that would accumulate in patients with impaired renal function and increase lactic acidosis risk.
Solution Approach 2:
The patent extracts the harmful systemic circulation pathway by using formulations (such as enteric-coated tablets or capsules) that prevent metformin from being absorbed into the bloodstream. Instead, the compound is directed to remain in the intestinal lumen where it exerts its therapeutic effect through local modulation of metabolic hormones, thereby removing the harmful systemic exposure while preserving the beneficial glucose control effects.
2Reliability
If metformin is administered to patients with impaired renal function, then glucose tolerance is improved, but the risk of metformin accumulation and lactic acidosis increases
Solution Approach 1:
The patent employs local quality by confining metformin action to the intestinal region through targeted formulation design. The enteric coating and modified release systems ensure the biguanide compound is released specifically in the upper or lower intestine, preventing its absorption into the systemic circulation and subsequent accumulation in patients with impaired renal function, while still achieving glucose tolerance improvement through local metabolic hormone modulation.
Solution Approach 2:
The patent extracts the accumulation problem by preventing metformin from entering the systemic circulation through specialized formulations. The enteric-coated tablets and capsules are designed to resist gastric acid and prevent intestinal absorption, thereby removing metformin from the systemic pool where it would otherwise accumulate in patients with reduced renal clearance, while maintaining therapeutic effect through local intestinal action.
3Reliability
If conventional metformin formulations are used, then therapeutic effects are achieved, but systemic bioavailability causes unwanted side effects and limited safety in certain patient groups
Solution Approach 1:
The patent applies local quality by designing formulations that deliver metformin specifically to the upper intestine, lower intestine, or both regions, rather than allowing systemic distribution. This localized delivery maintains therapeutic effects through local modulation of metabolic hormones while avoiding systemic side effects such as gastrointestinal disturbances, lactic acidosis, and other adverse reactions associated with conventional systemically-absorbed metformin.
Solution Approach 2:
The patent extracts the harmful systemic bioavailability by using enteric-coated formulations that prevent metformin absorption into the bloodstream. The coating is designed to protect the tablet or capsule from gastric acid and prevent intestinal absorption, thereby removing the compound from the systemic circulation and eliminating associated side effects while preserving therapeutic action through local intestinal mechanisms.
Data Source
AI summary
Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.